INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

20 окт 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

13 окт 2021 06:01:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

06 окт 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference

27 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

16 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics to Present at September Healthcare Investor Conferences

31 авг 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

05 авг 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

29 июл 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

02 июл 2021 15:01:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

29 июн 2021 20:08:30 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

28 июн 2021 15:01:00 Источник Nasdaq GlobeNewswire

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

26 июн 2021 10:15:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

24 июн 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

04 июн 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2021 Financial Results

06 май 2021 06:30:01 Источник Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates

29 апр 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting

27 апр 2021 15:35:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

12 апр 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis

30 мар 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors

25 мар 2021 06:30:00 Источник Nasdaq GlobeNewswire